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The autism spectrum disorders (ASDs) are a group of conditions
characterized by impairments in reciprocal social interaction and
communication, and the presence of restricted and repetitive beha-
viours1. Individuals with an ASD vary greatly in cognitive develop-
ment, which can range from above average to intellectual
disability2. Although ASDs are known to be highly heritable
( 90%)3, the underlying genetic determinants are still largely
unknown.Hereweanalysed the genome-wide characteristics of rare
(,1% frequency) copy number variation in ASDusing dense geno-
typing arrays. When comparing 996 ASD individuals of European
ancestry to 1,287 matched controls, cases were found to carry a
higher global burden of rare, genic copy number variants (CNVs)
(1.19 fold, P5 0.012), especially so for loci previously implicated in
eitherASDand/or intellectual disability (1.69 fold,P5 3.43 1024).
Among the CNVs there were numerous de novo and inherited
events, sometimes in combination in a given family, implicating
many novel ASD genes such as SHANK2, SYNGAP1, DLGAP2
and the X-linked DDX53–PTCHD1 locus. We also discovered an
enrichment of CNVs disrupting functional gene sets involved in
cellular proliferation, projection andmotility, and GTPase/Ras sig-
nalling. Our results reveal many new genetic and functional targets
in ASD that may lead to final connected pathways.
Twin and family studies indicate a predominantly genetic basis for
ASD susceptibility and provide support for considering these dis-
orders as a clinical spectrum. Some 5–15% of individuals with an
ASD have an identifiable genetic aetiology corresponding to known
rare single-gene disorders (for example, fragile X syndrome) and
chromosomal rearrangements (for example, maternal duplication of
15q11-q13). Rare mutations have been identified in synaptic genes,
includingNLGN3,NLGN4X (ref. 4) and SHANK3 (ref. 5), andmicro-
array studies have revealed copy number variation (CNV) as risk
factors6. CNV examples include de novo events observed in 5–10%
of ASD cases7–9, de novo or inherited hemizygous deletions and dupli-
cations of 16p11.2 (refs 9–11) andNRXN1 (ref. 7), and exceptionally
rare homozygous deletions in consanguineous families12. Genome-
wide association studies using single nucleotide polymorphisms
(SNPs) have highlighted two potential ASD risk loci at 5p14.1 (ref. 13)
and 5p15.2 (ref. 14), but these data indicate that common variation
will account for only a small proportion of the heritability in ASD.
To delineate further the contribution of rare genomic variants to
autism we genotyped 1,275 ASD cases and their parents using the
Illumina Infinium 1M single SNP microarray (Fig. 1). A set of
1,981 controls used for comparison studies was genotyped on the
same platform15 and both data sets were subjected to the same quality
control procedures.Ultimately, we analysed 996ASDcases (876 trios)
and 1,287 controls of European ancestry to minimize confounds due
to population differences (Supplementary Figs 1 and 2 and Sup-
plementary Table 1)16.
Two CNV prediction algorithms (QuantiSNP17 and iPattern (un-
published data)) and additional extensive quality control procedures
were used to establish a stringent data set of non-redundant CNVs
called by both algorithms in an individual (Fig. 1, Supplementary
Tables 1–3 and Supplementary Fig. 3). This stringent data set of 5,478
rare CNVs in 996 cases and 1,287 controls of European ancestry
(Supplementary Table 4) had the following characteristics: (1)
CNV present at ,1% frequency in the total sample (cases and con-
trols); (2) CNV $30 kb in size (because .95% of these could be
confirmed); and (3) all CNVs further verified using combined evid-
ence from the PennCNV algorithm18 and child–parent intensity fold
changes, genotype proportions (to verify deletions) and visual
inspection (for chromosome X).
We assessed the impact of rare CNV in cases compared to controls
using three primarymeasures ofCNVburden: thenumber ofCNVsper
individual, the estimatedCNV size, and thenumber of genes affected by
CNVs (Table 1). No significant difference was found in the former two
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Figure 1 | CNV discovery and characterization. Comprehensive procedures
were used to identify the rare CNV data set (boxed). Dashed arrows indicate
CNVs not included in downstream analyses. Labels a–f are as follows: a, SNP
and intensity quality control (QC) with ancestry estimation; b, QC for CNV
calls; c, pilot validation experiments using quantitative PCR were used to
evaluate the false discovery rate; d, rare CNVs in samples of European
ancestry were defined as$30 kb in size and present in the total sample set at
a frequency,1%. A total of 70 out of 996 (17%) of ASD cases were analysed
on different lower-resolution arrays in previous studies9,10,28. Label e
indicates that all CNVs were computationally verified and at least 40% of
case CNVs were also experimentally validated by qPCR and/or independent
Agilent or other SNP microarrays; f, 3,677 additional European ancestry
controls were used to test specific loci from the primary burden analyses.
Additional details are in the Methods and Supplementary Information. ID,
intellectual disability.
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measures (Supplementary Tables 4a and 5), even after controlling for
fine-level ancestry differences by pair-matching cases and controls
(Supplementary Information)16. In contrast, wediscovered a significant
increase in the number of genes intersected by rare CNV in cases when
focusing on gene-containing segments (1.19-fold increase, empirical
P5 0.012). This ASD association with genic CNV was stronger for
deletions (1.26-fold increase, empirical P5 8.03 1023). These dif-
ferences remained after we further controlled for potential case–control
differences that could be present due to biological differences or tech-
nical biases. Restricting our analysis to autosomal CNVs (that is, after
removing CNVs located on chromosome X) also resulted in a consis-
tent enriched gene count in ASD cases compared to controls. Single-
occurrence CNV deletions had increased rates in ASD cases over
controls, indicating that some could be pathogenic.
We then examined parent–child transmission and confirmed that
5.7% (50 out of 876) of ASD cases had at least one de novo CNV with
.0.6% carrying two or more de novo events (Supplementary Tables
4a, 6 and 7). The de novo CNV rate in our simplex and multiplex
families was 5.6% (22 out of 393) and 5.5% (19 out of 348), respec-
tively, in contrast with previous studies showing a higher rate in
simplex families8,9. A total of 226 validated de novo (7) and inherited
(219) CNVs not observed in controls and affecting single genes were
found (Supplementary Table 8).
Numerous novel candidate ASD loci such as SHANK2, SYNGAP1
and DLGAP2 were identified on the basis of the observation that de
novo CNV affects these genes in cases but not controls (Supplemen-
tary Table 6). The relatedness of SHANK2 to the causal ASD gene
SHANK3 (ref. 5), involvement of SYNGAP1 in intellectual disability19,
and interaction of DLGAP family proteins with SHANK proteins20
further support their role in ASDs. Maternally inherited X-linked
deletions at DDX53–PTCHD1 (7 cases) implicate this locus in ASD.
We tested an additional 3,677 European ancestry controls (Fig. 1) and
again foundnoCNVat these genes, andDDX53–PTCHD1 emerged as
a significant ASD risk factor (P5 3.13 1023 with the initial 1,287
controls; P5 3.63 1026 with combined controls; Supplementary
Fig. 4).
Table 1 | Global burden of genic rare CNVs in cases versus controls
Type Classification Total
CNVs (n)
P Case/control ratio Baseline rate (ctrl) Pcorr
None
All All 5,478 0.012* 1.19 3.59 0.003*
Deletions only All 2,757 0.008* 1.26 1.08 0.006*
Duplications only All 2,721 0.072 1.16 2.51 0.015*
CNV frequency
All 2–63 1,831 0.058 1.26 1.03 0.062
13 1,419 0.375 1.03 0.83 0.180
Deletions only 2–63 1,094 0.004* 1.57 0.43 0.011*
13 880 0.036* 1.26 0.30 0.036*
Duplications only 2-63 977 0.203 1.16 1.05 0.118
13 896 0.749 0.92 0.72 0.442
CNV size
All 30–500 kb 5,086 0.313 1.03 2.72 0.181
$500 kb 392 0.005* 1.69 0.88 0.005*
Deletions only 30–500 kb 2,645 0.004* 1.24 0.85 0.004*
$500 kb 112 0.209 1.32 0.23 0.143
Duplications only 30–500 kb 2,441 0.801 0.93 1.86 0.518
$500 kb 280 0.007* 1.82 0.65 0.012*
Table 1 shows gene count in cases versus controls. Total burden for genes intersected by CNVs in ASD cases (n5996) compared to controls (n5 1,287). Gene coordinates were defined by the
RefSeq boundaries plus a 10-kb region on either side. All genomic analyses used NCBI Build 36. Genome-wide P-values were estimated in 100,000 permutations (one-sided) and additionally
corrected (Pcorr) for global case–control differences in CNV rate and size. Analyses were further stratified according to CNV type (‘deletions only’ and ‘duplications only’) and frequency (single
occurrences (13) or CNVs observed two to six times in the total sample (2–63)). Note that for the two lower-frequency groups, the ‘deletions only’ and ‘duplications only’ counts are not expected to
sum to the ‘all’ count (see ref. 26 and Supplementary Information).
* Significant differences (P#0.05) are indicated.
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Figure 2 | CNV burden in known ASD and/or intellectual disability genes.
a, Proportion of samples with CNVs overlapping genes and loci known to be
associated in ASD with or without intellectual disability (ID) or intellectual
disability only, as well as published candidate genes and loci for ASD
(Supplementary Table 9). To select for CNVs with maximal impact, they
needed to intersect genes and overlap the target loci by$50%of their length.
Fisher’s exact test P-values for significant differences (P# 0.05, one tailed)
are shown. NS, not significant. b, Enrichment analysis for genes overlapped
by rare CNVs in cases compared to controls for the three gene sets in
a, relative to the whole genome. Odds ratio and 95% confidence intervals are
given for each gene set. Empirical P-values for gene-set enrichment are
indicated above each odds ratio. All P-values ,0.1 are listed.
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Association studies of individual rare CNV often have insufficient
power to discriminate benign from disease-causing variants. Here,
we assessed whether genes and CNVs previously associated with ASD
and/or intellectual disability were enriched in cases compared with
controls, in order to help identify pathogenic events. We defined
three gene lists based on evidence from previous studies of their
involvement in ASDs (Supplementary Table 9): (1) ‘ASD implicated’
list consisting of 36 disease genes and 10 loci strongly implicated in
ASD and identified in subjects with ASD or ASD and intellectual
disability; (2) ‘intellectual disability’ consisting of 110 disease genes
and 17 loci implicated in intellectual disability but not yet in ASD;
and (3) ‘ASD candidates’ including 103 genes from previous studies
of common and rare variants.
We observed a higher proportion of cases with rare CNVs overlap-
ping ‘ASD implicated’ disease genes compared to controls (4.3% ver-
sus 2.3%, Fisher exact test P5 5.43 1023; Fig. 2a), corresponding to a
significant enrichment for genes in this set (odds ratio (OR)5 1.8;
95% confidence interval (CI) 1.3–2.6, empirical P5 2.63 1023;
Fig. 2b, see also Supplementary Information). This effect was stronger
for duplications, which may also disrupt genes (OR5 2.3; 95% CI
1.4–3.8, empirical P5 9.43 1024). Enrichment was also found for
rare CNVs overlapping intellectual disability genes, more notably for
deletions (OR5 2.1; 95% CI 1.1–4.2, empirical P5 0.053). In con-
trast, there was no evidence of enrichment among case CNVs com-
pared to control CNVs for genes in the ASD candidates set (empirical
P. 0.3). When the two disease gene sets ‘ASD implicated’ and ‘intel-
lectual disability’ were combined, we observed 7.6% of cases with rare
CNVs preferentially affecting ASD/intellectual disability genes com-
pared to 4.5% in controls (Fisher exact test P5 1.23 1023; Fig. 2a).
The observed enrichments didnot changewhenpotential case–control
genome-wide differences for CNV rate and size were considered.
Our global analyses of these putative pathogenic loci use subjective
boundaries for CNV overlap. Manual inspection of the data yields
more accurate results. After eliminating CNVs that are less likely to
have an aetiological role (heterozygous CNVs that disrupt autosomal
recessive loci, events outside the critical region of overlap of genomic
disorders, X-linked genes in females inherited from non-ASD fathers,
duplications inherited from non-ASD parents, and intronic CNVs in
NRXN1), 25CNVs remained in theASDgroup, compared toonly four
in the controls (P5 3.63 1026; Supplementary Table 10). Moreover,
the latter four CNVs were all duplications at 1q21.1, 16p11.2 or
22q11.2, loci known to exhibit incomplete penetrance and variable
expressivity6. The population attributable risk provided by the com-
bination of all ASD CNVs that overlap ASDs and/or intellectual
disability genes is estimated to be 3.3% (Supplementary Table 11).
We also identified rare de novo chromosomal abnormalities and large
CNVs likely to be aetiological (Supplementary Table 10).
We then tested for functional enrichment of gene sets among those
genes affected by CNVs to identify biological processes involved in
ASD (Fig. 3). Here, the term gene set refers to groups of genes that
share a common function or operate in the same pathway. Such a
functional enrichment mapping approach can combine single-gene
effects into biologically meaningful groups21.
We compiled comprehensive collections of gene sets (Supplemen-
tary Table 12) and used the Fisher’s exact test to assess which gene sets
were more frequently affected by rare CNV events in ASD cases com-
pared to controls.An estimate of the false-discovery rate (FDR) at each
gene set was obtained by random permutation of case and control
labels (Supplementary Information). To visualize enriched gene sets,
overlap scores were used to organize these sets graphically into a
functional enrichmentmap (or network) usingCytoscape22.We iden-
tified the ‘seed’ gene sets for the network at an FDR q-value of 5% and
further relaxed the thresholds to 12.5% to better capture the network
topology23.
Using these criteria only deletions were found to be significantly
enriched in gene sets in cases over controls (Supplementary Fig. 5),
consistent with the global burden results (Table 1). Specifically, 76
gene sets affected by deletions (2.18% of sets tested) were found to be
enriched and used to construct a functional map (Fig. 3a and
Supplementary Figs 6 and 7). We tested for possible bias, including
measures of CNV size and number for cases versus controls per gene
set, as well as genome proximity, but no differences were found that
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Figure 3 | A functional map of ASD. Enrichment results were mapped as a
network of gene sets (nodes) related by mutual overlap (edges), where the
colour (red, blue or yellow) indicates the class of gene set. Node size is
proportional to the total number of genes in each set and edge thickness
represents the number of overlapping genes between sets. a, Gene sets
enriched for deletions are shown (red) with enrichment significance (FDR
q-value) represented as a node colour gradient. Groups of functionally
related gene sets are circled and labelled (groups, filled green circles;
subgroups, dashed line). b, An expanded enrichment map shows the
relationship between gene sets enriched in deletions (a) and sets of known
ASD/intellectual disability genes. Node colour hue represents the class of
gene set (that is, enriched in deletions, red; knowndisease genes (ASDand/or
intellectual disability (ID) genes), blue; enriched only in disease genes,
yellow). Edge colour represents the overlap between gene sets enriched in
deletions (green), from disease genes to enriched sets (blue), and between
sets enriched in deletions and in disease genes or between disease gene-sets
only (orange). The major functional groups are highlighted by filled circles
(enriched in deletions, green; enriched in ASD/intellectual disability, blue).
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might explain the observed enrichments (Supplementary Figs 8
and 9).
We identified enrichments in gene sets known to be involved in
ASDs and also discovered new candidate ASD pathways (Fig. 3a and
Supplementary Table 13). For example, gene sets involved in cell and
neuronal development and function (including projection, motility
and proliferation) previously reported in ASD-associated pheno-
types were identified24. Novel observations included gene sets
involved in GTPase/Ras signalling, with component Rho GTPases
known to be involved in regulating dendrite and spine plasticity
and associated with intellectual disability. We also found a tentative
link to sets in the kinase activity/regulation functional group where
only minorities of these sets meet a stringent 5% FDR q-value thresh-
old (Supplementary Fig. 10).
We further assessed the relationship of our functional enrichment
map with known ASD/intellectual disability genes (Fig. 3b and
Supplementary Fig. 11) and found genes enriched in sets linked to
microtubule cytoskeleton, glycosylation and CNS development/
adhesion25. The two groups of genes found to be enriched in deletions
(Fig. 3a) also displayed connectivity to the ASD/intellectual disability
disease gene sets, either directly or through intermediates (Fig. 3b and
Supplementary Fig. 12). Although ASD genes seem to be enriched in
different subsets of genes compared to intellectual-disability-only
genes, we cannot discount the possibility that this is the result of
selection bias, and we expect that more intellectual disability genes
may yet be linked to ASD.
Our findings provide strong support for the involvement of mul-
tiple rare genic CNVs, both genome-wide and at specific loci, in ASD.
These findings, similar to those recently described in schizophrenia26,
suggest that at least some of these ASDCNVs (and the genes that they
affect) are under purifying selection27. Genes previously implicated in
ASD by rare variant findings have pointed to functional themes in
ASD pathophysiology6,28. Molecules such as NRXN1, NLGN3/4X
and SHANK3, localized presynaptically or at the post-synaptic density
(PSD), highlight maturation and function of glutamatergic synapses.
Our data reveal that SHANK2, SYNGAP1 and DLGAP2 are new ASD
loci that also encode proteins in the PSD. We also found intellectual
disability genes to be important in ASD29. Furthermore, our func-
tional enrichment map identifies new groups such as GTPase/Ras,
effectively expanding both the number and connectivity of modules
that may be involved in ASD. The next step will be to relate defects or
patterns of alterations in these groups to ASD endophenotypes. The
combined identification of higher-penetrance rare variants and new
biological pathways, including those identified in this study, may
broaden the targets amenable to genetic testing and therapeutic
intervention.
METHODS SUMMARY
Raw data from ASD family (accession phs000267.v1.p1) and SAGE control
(Accession: phs000092.v1.p1) genotyping are at NCBI dbGAP. CNVs were ana-
lysed using PLINK v1.0730, R stats and custom scripts. See Supplementary
Information for details. A list of all CNVs passing quality control is available
in Supplementary Table 8.
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